findmyKOL

Ann Partridge, MD, MPH

Enriched profile

Chief Clinical Strategy Officer and Vice Chair, Department of Medical Oncology, Dana-Farber Cancer Institute; Eric P. Winer, MD, Chair in Breast Cancer Research; Professor of Medicine, Harvard Medical School · Dana-Farber Cancer Institute

ORCID↗NPI↗
✓ Full profile
Region🇺🇸 Boston, MA · Northeast · United StatesSpecialtyMedical OncologyFocusBreast Cancer Treatment Studies+4
Active KOLfindmyKOL type: EliteLatest publication2026Online presenceverified 2026Payments2021–2025NIH funding2006–2024

Ann Partridge is Chief Clinical Strategy Officer and Vice Chair, Department of Medical Oncology, Dana-Farber Cancer Institute; Eric P. Winer, MD, Chair in Breast Cancer Research; Professor of Medicine, Harvard Medical School at Dana-Farber Cancer Institute. OpenAlex indexes 1,042 publications with 47,329 citations (h-index 102); ClinicalTrials.gov lists 11 registered studies with this person as an investigator. By OpenAlex citation count, this profile ranks in the top 10% of Medical Oncology profiles in the findmyKOL directory.

Data verified 16 Oct 2026

Overview

Updated 16 Oct 2026

Ann Partridge, MD MPH, is Chief Clinical Strategy Officer and Vice Chair, Department of Medical Oncology, Dana-Farber Cancer Institute. The public record shows 1,042 publications with 47,329 citations (h-index 102), centered on Breast Cancer Treatment Studies, Cancer Risks and Factors, Cancer survivorship and care. It also documents an investigator role on 11 registered clinical trials, industry payments reported by 4 companies, 3 NIH-funded awards (2006–2024).

  • Most recent indexed publication: 2026 · Clinical cancer research
  • Top research focus: Breast Cancer Treatment Studies
  • 11 registered trials on ClinicalTrials.gov
  • Open Payments reporting from 4 companies

Generated from the cited public record · current as of 16 Oct 2026. Every fact links its source below.

Indications focus

from trials led + research topics
Breast Cancer10 trialsCarcinoma, Intraductal, Noninfiltrating1 trialCarcinoma in Situ1 trialCarcinoma, Ductal1 trialInfertility1 trial

Research focus

OpenAlex concept fingerprint
Breast Cancer Treatment StudiesCancer Risks and FactorsCancer survivorship and careBRCA gene mutations in cancerReproductive Biology and Fertility

Drugs & molecules

across trials, industry payments and publications
Enhertugeneric · TrastuzumabClinical trials—Industry payments4Publications14Ibrancegeneric · PalbociclibClinical trials—Industry payments2Publications2Kisqaligeneric · RibociclibClinical trials—Industry payments1Publications1Tukysageneric · TucatinibClinical trials—Industry payments2Publications—

Works with

trial sponsors and companies reporting payments
Dana-Farber Cancer InstituteClinical trials8Industry payments—Pfizer Inc.Clinical trials—Industry payments5AstraZeneca Pharmaceuticals LPClinical trials—Industry payments4Gilead Sciences, Inc.Clinical trials—Industry payments4Alliance Foundation Trials, LLC.Clinical trials1Industry payments—Novartis Pharmaceuticals CorporationClinical trials—Industry payments1SWOG Cancer Research NetworkClinical trials1Industry payments—Weill Medical College of Cornell UniversityClinical trials1Industry payments—

Scholarship

indexed output and impact (OpenAlex)
View publications ↓
1,042publications

Distinct works indexed by OpenAlex, matched via ORCID; 95 in PubMed.

47,329citations

Total citations across indexed works.

102h-index

Hirsch index (OpenAlex). i10-index 383.

Clinical & industry

trials, payments and federal funding
11clinical trials

Investigator role on registered studies.

View trials ↓
4companies · 2021–2025

Companies reporting payments to CMS. Facts, not judgments.

View payments ↓
3NIH grants · 2006–2024

Federally funded research awards.

View funding ↓

Public positions

sourced statements on record
  • Chair

    CDC Advisory Committee on Breast Cancer in Young Women

    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →en.wikipedia.org ↗

Contact

The practice address and phone this provider lists in the federal NPPES (CMS) registry.

Practice address

Telephone

Practice address and telephone from the federal NPPES registry.

Sign in to view contact details →

Clinical trials

Updated 16 Oct 2026

Listed as an investigator on 11 registered studies on ClinicalTrials.gov. The most recent:

All 11 trial records: search, sort and filter.Explore →

Industry payments

Updated 16 Oct 2026

4 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:

All 8 payment records: search, sort and filter.Explore →
View the CMS Open Payments record ↗

Medicare prescribing footprint (2024)

The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.

  • Cancer & immunology

    100%
    Aromatase Inhibitor72.9%
    Letrozole100%
    Part D≥11 patients
    Kinase inhibitor27.1%
    Kisqali100%
    Part D<11 patients
Where care is delivered (Part B)100% facility · 0% office

Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.

NIH funding

Updated 16 Oct 2026

3 NIH research awards on record, funded 2006–2024 per NIH RePORTER. The latest:

All 12 award records: search, sort and filter.Explore →

Congress activity

Updated 16 Oct 2026

213 congress contributions (2004–2026) across AACR, ASCO, ASTRO, ESMO, SABCS per OpenAlex. The most recent:

All 213 congress records: search, sort and filter.Explore →

Published abstracts are attributed via the same ORCID-disambiguated authorship as publications, so each is DOI-verified. Podium roles (invited talks, session chairs) and oral/poster type are added as program data is confirmed.

Publications

Updated 16 Oct 2026

Their five most recent publications, matched to their ORCID record and linked to PubMed.

All 95 publications: search, sort and filter.Explore →

Most-cited works

by citation count (OpenAlex)
  1. 01
    Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013
    Article3,737 citations2013
    doi.org ↗
  2. 02
    American Society of Clinical Oncology Recommendations on Fertility Preservation in Cancer Patients
    Article2,052 citations2006
    doi.org ↗
  3. 03
    Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015
    Article1,844 citations2015
    doi.org ↗
  4. 04
    Fertility Preservation for Patients With Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update
    Article1,614 citations2013
    doi.org ↗
  5. 05
    Fertility Preservation in Patients With Cancer: ASCO Clinical Practice Guideline Update
    Article1,483 citations2018
    doi.org ↗
All 1,042 cited works: search, sort and filter.Explore →

Network

Updated 16 Oct 2026

The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.

Shoshana M. Rosenberg279Eric P. Winer237Kathryn J. Ruddy183Gregory J. Kirkner151Virginia F. Borges143Craig Snow132Lidia Schapira121Steven E. Come120Donna Neuberg117Jeffrey Peppercorn111Lisa A. Carey110Tal Sella109Rulla M. Tamimi103Sara M. Tolaney94Laura C. Collins93Ian E. Krop84Deborah Dillon81Erica L. Mayer78Heather A. Parsons78Peter G. Miller78Christopher J. Gibson77Shari Gelber77Nancy U. Lin76Ashka Patel76Alexander G. Bick75Geoffrey Fell75Adam S. Sperling75Philip D. Poorvu74Kathy D. Miller71Nikhil Wagle68Ellen Warner62Matteo Lambertini56Melissa E. Hughes55Fedro A. Peccatori52Daniel G. Stover49Lorenzo Trippa49Harold J. Burstein48Jennifer A. Ligibel46Beverly Moy45Yue Zheng45

Online presence

Updated 16 Oct 2026

This person's own public accounts first, then places where others mention them. Two different things, listed separately.

Owned accounts

public accounts run by this person
  • Doximity

    doximity.com/pub/ann-partridge-md

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com ↗

We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.

Background & recognition

Updated 16 Oct 2026

Credentials, appointments and honors, newest first, each linked to the public source it came from.

Education

degrees and training on record
  • Board Certified

    Medical Oncology

    2001
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →dana-farber.org ↗
  • Board Certified

    Internal Medicine

    1998
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →dana-farber.org ↗
  • MD

    Weill Cornell Medicine

    1995
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →dana-farber.org ↗
  • BS

    Georgetown University

    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →en.wikipedia.org ↗
  • MPH

    Harvard T.H. Chan School of Public Health

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →dana-farber.org ↗

Editorial & leadership roles

journal and society appointments
  • Member

    ASCO Board of Directors

    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →bcrf.org ↗
  • Co-chair

    NCI Alliance for Clinical Trials in Oncology Breast Committee

    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →bcrf.org ↗
  • Member

    NCI Breast Cancer Steering Committee

    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →bcrf.org ↗
  • Chief Scientific Advisor

    Susan G. Komen

    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →bcrf.org ↗
  • Clinical Research Professor

    American Cancer Society

    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →en.wikipedia.org ↗
  • Founder and Director

    Young and Strong Program for Young Adults with Breast Cancer, Dana-Farber

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →dana-farber.org ↗
  • Director

    Adult Survivorship Program, Dana-Farber

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →bcrf.org ↗

Awards & honors

honors on the public record

Secondary affiliations

appointments beyond the home institution

Media & interviews

press, podcasts and appearances
  • Podcast guest

    "The Good News About Cancer"

    2025
    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →podcasts.apple.com ↗
  • Video interview

    "Breast cancer in young women: Dr. Ann Partridge", Dana-Farber Cancer Institute (YouTube)

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →youtube.com ↗
  • Podcast

    "Investigating Breast Cancer: Dr. Ann Partridge", Breast Cancer Research Foundation

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →bcrf.org ↗

Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.

Similar KOLs

Other experts from the same institution or the same specialty.